{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:06:57Z","timestamp":1787022417786,"version":"build-2736575974"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej18-0328","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T17:31:34Z","timestamp":1551202294000},"page":"295-300","source":"Crossref","is-referenced-by-count":22,"title":["Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody\u2014insight into the pathogenesis of autoimmune endocrinopathy\u2014"],"prefix":"10.1507","volume":"66","author":[{"given":"Sumie","family":"Okahata","sequence":"first","affiliation":[{"name":"Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Mitsumatsu","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Noso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka 589-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka 589-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Shiba","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, et al. (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24: 724\u2013730.","DOI":"10.1038\/s41591-018-0040-8"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Andrioli M, Pecori Giraldi F, Cavagnini F (2006) Isolated corticotrophin deficiency. Pituitary 9: 289\u2013295.","DOI":"10.1007\/s11102-006-0408-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, et al. (2005) Autoimmune hypophysitis. Endocr Rev 26: 599\u2013614.","DOI":"10.1210\/er.2004-0011"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Syriou V, Moisidis A, Tamouridis N, Alexandraki KI, Anapliotou M (2008) Isolated adrenocorticotropin deficiency and flexion contractures syndrome. Hormones (Athens) 7: 320\u2013324.","DOI":"10.14310\/horm.2002.1213"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, et al. (2005) Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 90: 1323\u20131331.","DOI":"10.1210\/jc.2004-1300"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Karavitaki N, Wass J, Henderson Slater JD, Wade D (2006) A case of post-traumatic isolated deficiency with spontaneous recovery 9 months after the event. J Neurol Neurosurg Psychiatry 77: 276\u2013277.","DOI":"10.1136\/jnnp.2005.070482"},{"key":"#cr-split#-7.1","unstructured":"7 Yamamoto T, Kamoi K (2008) Prevalence of maturity-onset isolated ACTH deficiency"},{"key":"#cr-split#-7.2","unstructured":"(IAD) in 2005: Japanese cohort studies. Endocr J 55: 939-941."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ohara N, Kojima N, Sato T, Ikarashi T, Sone H, et al. (2015) Type 1 diabetes mellitus and isolated adrenocorticotropin deficiency manifested by parkinsonism: a case report and literature review. Intern Med 54: 2629\u20132635.","DOI":"10.2169\/internalmedicine.54.5022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, et al. (2014) Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99: 4078\u20134085.","DOI":"10.1210\/jc.2014-2306"},{"key":"10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"10 Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment and biologic insights. Pituitary 19: 82\u201392.","journal-title":"Pituitary","ISSN":"https:\/\/id.crossref.org\/issn\/1386-341X","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D; Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804\u2013816.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195\u2013207.","DOI":"10.1038\/nrendo.2016.205"},{"key":"13","unstructured":"13 Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, et al. (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6: 230ra45."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, et al. (2016) Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186: 3225\u20133235.","DOI":"10.1016\/j.ajpath.2016.08.020"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Bando H, Iguchi G, Kanie K, Nishizawa H, Matsumoto R, et al. (2018) Isolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndrome. Pituitary 21: 480\u2013489.","DOI":"10.1007\/s11102-018-0901-7"},{"key":"16","unstructured":"16 Gaudy C, Cl\u00e9vy C, Monestier S, Dubois N, Pr\u00e9au Y, et al. (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38: e182\u2013e183."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ikegami H, Kawabata Y, Noso S (2016) Immune checkpoint therapy and type 1 diabetes. Diabetol Int 7: 221\u2013227.","DOI":"10.1007\/s13340-016-0276-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Tsiogka A, Jansky GL, Bauer JW, Koelblinger P (2017) Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma. Melanoma Res 27: 524\u2013525.","DOI":"10.1097\/CMR.0000000000000384"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, et al. (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67: 1471\u20131480.","DOI":"10.2337\/dbi18-0002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13: 195\u2013207.","DOI":"10.1038\/nrendo.2016.205"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Granados HM, Draghi A, Tsurutani N, Wright K, Fernandez ML, et al. (2017) Programmed cell death-1, PD-1, is dysregulated in T cells from children with new onset type 1 diabetes. PLoS One 12: e0183887.","DOI":"10.1371\/journal.pone.0183887"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, et al. (2017) Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. Diabetes Res Clin Pract 133: 10\u201312.","DOI":"10.1016\/j.diabres.2017.07.036"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, et al. (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198: 63\u201369.","DOI":"10.1084\/jem.20022125"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Wang B, Du W, Jia Y, Zhang X, Ma G (2017) Cytotoxic T-lymphocyte-associated protein 4 +49A\/G polymorphisms contribute to the risk of type 1 diabetes in children: an updated systematic review and meta-analysis with trial sequential analysis. Oncotarget 8: 10553\u201310564.","DOI":"10.18632\/oncotarget.14457"},{"key":"25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dc08-0280","volume":"31","author":"E Kawasaki","year":"2008","unstructured":"25 Kawasaki E, Imagawa A, Makino H, Uga M, Abiru N, et al. (2008) Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Diabetes Care 31: 1608\u20131610.","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Momin S, Flores S, Angel BB, Codner DE, Carrasco PE, et al. (2009) Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. Diabetes Res Clin Pract 83: 289\u2013294.","DOI":"10.1016\/j.diabres.2008.12.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Kracht MJL, Zaldumbide A, Roep BO (2016) Neoantigens and microenvironment in type 1 diabetes: lessons from antitumor immunity. Trends Endocrinol Metab 27: 353\u2013362.","DOI":"10.1016\/j.tem.2016.03.013"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Ant\u00f3n LC, Yewdell JW (2014) Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J Leukoc Biol 95: 551\u2013562.","DOI":"10.1189\/jlb.1113599"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/4\/66_EJ18-0328\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T23:19:09Z","timestamp":1556320749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/4\/66_EJ18-0328\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0328","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}